Company: MDCXW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001062993-25-014058
Chunk: 92

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 8
Chunk 92
---
 attributable to ordinary shareholders was calculated as follows:

              Three months ended June 30,

              Six months ended June 30,

              2025

              2024

              2025

              2024

              Net loss attributable to shareholders
              $
              (6,176,084
              )
              $
              (3,632,859
              )
              $
              (11,278,492
              )
              $
              (5,340,217
              )

              Weighted average number of common shares outstanding during the year
               
              14,284,261

              8,167,993

              13,853,305

              8,122,333

              Basic and diluted net loss per share attributable to shareholders
              $
              (0.43
              )
              $
              (0.44
              )
              $
              (0.81
              )
              $
              (0.66
              )

      The Company's potentially dilutive securities for the three and six months ended June 30, 2025 and 2024, include stock options, warrants, and notes payable. The Company excluded the potential ordinary shares outstanding at each period end from the computation of diluted net loss per share attributable to ordinary shareholders for the three and six months ended June 30, 2025 and 2024 because including them would have had an anti-dilutive effect.

      8. Related party transactions
      On October 18, 2023, the Company signed an agreement with RBx Capital, LP ("RBx"), a family office controlled by the Company's Executive Chairman and CEO, that provides for certain managerial positions to be filled from within RBx. RBx is responsible for the payment and provision of all wages, bonuses, and benefits for these positions. Reimbursable salaries paid to RBx pursuant to this agreement are $125,000 per month. In December 2024, reimbursable salaries were changed to $100,000 per month. Reimbursable salaries paid to RBx were $300,000 and $375,000 during the three months ended June 30, 2025 and 2024, respectively. Reimbursable salaries paid to RBx were $600,000 and $675,000 during the six months ended June 30, 2025 and 2024, respectively. Additional expenses of $64,046 and $38,770 were incurred by RBx on behalf of the